# A Randomized, Double-Blind, Placebo-Controlled Study to Assess the Safety and Efficacy of KRP-104 in Patients With Type 2 Diabetes Inadequately Controlled on Metformin Alone

> **NCT00525330** · PHASE2 · COMPLETED · sponsor: **ActivX Biosciences, Inc.** · enrollment: 213 (actual)

## Conditions studied

- Type 2 Diabetes

## Interventions

- **DRUG:** KRP-104 QD Drug: Placebo Drug: Metformin
- **DRUG:** Placebo Drug: Metformin
- **DRUG:** KRP-104 BID Drug: Placebo Drug: Metformin

## Key facts

- **NCT ID:** NCT00525330
- **Lead sponsor:** ActivX Biosciences, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-09
- **Primary completion:** 2008-08
- **Final completion:** 2008-08
- **Target enrollment:** 213 (ACTUAL)
- **Last updated:** 2013-08-22

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00525330

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00525330, "A Randomized, Double-Blind, Placebo-Controlled Study to Assess the Safety and Efficacy of KRP-104 in Patients With Type 2 Diabetes Inadequately Controlled on Metformin Alone". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT00525330. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*